Manufactured Object – Page 5

A Concerning Pattern: Pharma Mulls UK Divestments as Government Action Lags in Life Sciences

3 months ago talkbio0Tagged AstraZeneca, Biological Science Disciplines, drug price, drug spending, eli lilly, Government, Investments, Merck, Nance-Horan syndrome, pharmaceutical divestment, Policy, R&D, sanofi, UK

UK life sciences; pharmaceutical divestment; Merck; AstraZeneca; Sanofi; Eli Lilly; R&D investment; drug pricing; government policy; NHS drug spending

AstraZeneca Pauses £200M Expansion in UK Amid Pharma Uncertainty

3 months ago talkbio0Tagged AstraZeneca, Cambridge, expansion, Investments, Pauses, Pharma, UK

AstraZeneca; UK Pharma; Investment; Cambridge; Expansion Pause

Eli Lilly Pauses UK Biotech Incubator Plans Amid Concerns Over NHS Drug Pricing

3 months ago talkbio0Tagged Biological Science Disciplines, biotech incubator, biotech industry, Eli, Eli Lilly, Gateway Labs, Government, Investments, Nance-Horan syndrome, Pauses, pharmaceutical innovation, UK

Eli Lilly; Gateway Labs; UK biotech incubator; pause; investment; NHS drug spending; life sciences; biotech industry; government funding; pharmaceutical innovation

Merck Moves All R&D Operations Out of UK, Citing Unfavorable Environment

3 months ago talkbio0Tagged Biological Science Disciplines, Brexit impact, Drug Discovery, Government, Investments, layoffs, London Bioscience Innovation Centre, Merck, Multiple Sulfatase Deficiency Disease, Relocation of home or business, UK

Merck; MSD; R&D relocation; UK life sciences; drug discovery; Brexit impact; London Bioscience Innovation Centre; Francis Crick Institute; government investment; layoffs

Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

3 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Biotechnology, epigenetic therapy, Epigenic, Gene Silencing, Hepatitis B, Hypercholesterolemia, Investments, NRG, Parkinson Disease, Series B funding

Epigenic Therapeutics; NRG Therapeutics; Series B funding; epigenetic therapy; hepatitis B; hypercholesterolemia; Parkinson’s disease; ALS; biotechnology investment; gene silencing

Eli Lilly Touts ‘Striking’ Progression-Free Survival Results for Jaypirca in New Front-Line CLL Study

3 months ago talkbio0Tagged BRUIN, BTK inhibitor, Chronic Lymphocytic Leukemia, Clinical Trials, CLL, CLL-313, eli lilly, expansion, First line treatment, Jaypirca, Labels (device), Progression-Free Survival

Jaypirca; Eli Lilly; CLL; chronic lymphocytic leukemia; BRUIN CLL-313; progression-free survival; BTK inhibitor; first-line treatment; clinical trial; label expansion

Enveda Raises $150M Series D, Advances Nature-Inspired Drug Programs

3 months ago talkbio0Tagged Biosciences, Dermatitis, Atopic, Enveda, Immune System Diseases, Investments, Mikael, nature-inspired drug discovery, Series D

Enveda Biosciences; Series D funding; $150 million; nature-inspired drug discovery; atopic dermatitis; immune diseases; Mikael Dolsten; biotech investment

Atlas Venture Raises $400M Opportunity Fund to Bolster Biotech Portfolio

3 months ago talkbio0Tagged Biopharma, biotech startups, Cervical Atlas, Investments, Late stage, M growth fund, Opportunity Fund III, portfolio support, venture

Atlas Venture; $400M growth fund; biotech startups; Opportunity Fund III; portfolio support; venture capital; late-stage funding; biopharma investment

Gilead Unveils New Manufacturing Site in California as Part of $32B U.S. Investment Plan

3 months ago talkbio0Tagged Billion, Biological Factors, California, economic impact, expansion, Foster City, Gilead Sciences, Investments, Manufacturing, Manufacturing Facilities, R&D, Surgical construction, United States

Gilead Sciences; Foster City; California; manufacturing facility; biopharmaceuticals; $32 billion investment; economic impact; expansion; R&D; job creation; U.S. manufacturing

UK Pharma Trade Group Calls for Overhaul of Government’s Life Sciences Investment Evaluation and Medicines Pricing Schemes

3 months ago talkbio0Tagged ABPI, Biological Science Disciplines, Evaluation, government review, innovation, Investments, Nance-Horan syndrome, pharma trade group, Pricing, statutory scheme, UK, valproic acid glucuronide

UK life sciences; ABPI; VPAG; pharma trade group; investment evaluation; medicines pricing; government review; NHS; innovation; statutory scheme